Evaluation of eltrombopag in patients with aplastic anemia in real-world experience

Akiko Konishi; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Ryo Saito; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura

doi:10.1016/j.lrr.2019.03.002

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience

Leuk Res Rep. 2019 Mar 5:11:11-13. doi: 10.1016/j.lrr.2019.03.002. eCollection 2019.

Authors

Akiko Konishi^{1

2}, Aya Nakaya^{1

2}, Shinya Fujita^{1

2}, Atsushi Satake^{1

2}, Takahisa Nakanishi^{1

2}, Yoshiko Azuma^{1

2}, Yukie Tsubokura^{1

2}, Ryo Saito^{1

2}, Masaaki Hotta^{1

2}, Hideaki Yoshimura^{1

2}, Kazuyoshi Ishii^{1

2}, Tomoki Ito^{1

2}, Shosaku Nomura^{1

2}

Affiliations

¹ First Department of Internal Medicine, Kansai Medical University, Japan.
² Departments of Pathology and Laboratory Medicine, Kansai Medical University, Japan.

Abstract

Background: Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown.

Methods: We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018.

Results: Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders.

Conclusion: Eltrombopag is a promising agent for treating patients with any degree of AA.

Keywords: Aplastic anemia; Eltrombopag; Neutrophil-to-lymphocyte ratio; Real-world setting.